Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29649478 | 0.89 | SSTR3 (0.44) | SSTR3CTSLPTPN1HDAC8SIRT1 | |
| SCHEMBL26015746 | 0.89 | SIRT5 (0.45) | SSTR3 | |
| SCHEMBL17741052 | 0.89 | HTR2A (0.41) | SSTR3PTPN1SIRT1SIRT2SIRT3 | |
| SCHEMBL13410176 | 0.85 | TGM2 (0.41) | SSTR3PTPN1SIRT1SIRT2SIRT3 | |
| SCHEMBL13401556 | 0.85 | TGM2 (0.41) | SSTR3PTPN1SIRT1SIRT2SIRT3 | |
| SCHEMBL30895569 | 0.84 | PTPN1 (0.45) | SSTR3CTSLPTPN1 | |
| SCHEMBL12972289 | 0.84 | PTPN1 (0.47) | PTPN1SIRT1SIRT2SIRT3 | |
| SCHEMBL2734926 | 0.84 | PTPN1 (0.47) | PTPN1SIRT1SIRT2SIRT3 | |
| SCHEMBL25361722 | 0.84 | PTPN1 (0.43) | SSTR3CTSLPTPN1SIRT1SIRT2 | |
| SCHEMBL25361716 | 0.84 | PTPN1 (0.43) | SSTR3CTSLPTPN1SIRT1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | SSTR3 3591/4885CTSL 1742/4885PTPN1 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.